Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Treatment Gaps Abound in Heart Failure but Can Be Closed, Studies Show

News Conference News ESC Heart Failure 2024

Treatment Gaps Abound in Heart Failure but Can Be Closed, Studies Show

Michael O'Riordan

May 21, 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

News Conference News ESC 2023

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

September 01, 2023

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

News Conference News ESC 2023

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

August 30, 2023

GDMT With ARNI Lessens MR, Perhaps Obviating Need for Interventions

News Conference News HFSA 2022

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

Michael O'Riordan

October 04, 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

Non-COAPT-Like Patients Fare Well With MitraClip, EXPAND Suggests

News Conference News TVT 2022

Non-COAPT-Like Patients Fare Well With MitraClip, EXPAND Suggests

Michael O'Riordan

June 09, 2022

New HF Guidelines Stress Four Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

April 01, 2022

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

News Conference News AHA 2021

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Michael O'Riordan

November 19, 2021

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.